Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184504 | 0.92 | TDP1 (0.54) | ALDH1A1TDP1GAAKMT2AMEN1 | |
| SCHEMBL25791341 | 0.92 | TDP1 (0.54) | ALDH1A1TDP1GAAKMT2AMEN1 | |
| SCHEMBL24017075 | 0.81 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL24017076 | 0.81 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8239398 | 0.79 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL13462356 | 0.79 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6422240 | 0.79 | AOC3 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL327954 | 0.79 | CA1 (0.56) | CA1CA2CA12CA7CA9 | |
| SCHEMBL22299837 | 0.77 | CA1 (0.48) | CA1CA2CA12CA7CA9 | |
| Hydrochloric Acid SCHEMBL3654829 | 0.77 | CA1 (0.55) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535594-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-12-27 | — | — | US | disclosed |
| EP-3728191-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2022-07-13 | — | — | EP | disclosed |
| US-20210107875-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-04-15 | — | — | US | disclosed |
| US-9365614-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-06-14 | — | — | US | disclosed |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | PHARMASCIENCE INC. (CA) | 2014-11-13 | — | — | US | disclosed |
| US-8765681-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-03-21 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-7645741-B2 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | AEGERA THERAPEUTICS, INC. | 2010-01-12 | — | — | US | disclosed |
| US-7579320-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2009-08-25 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | PHARMASCIENCE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | AEGERA THERAPEUTICS, INC. (CA) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | CA1 1723/4885CA2 1325/4885CA12 2195/4885 |
| US-20140336134-A1 | IAP BIR Domain Binding Compounds | BIRC2, BIRC7, BIRC5 | CA1 2484/4885CA2 2014/4885CA12 2830/4885 |
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | CA1 2550/4885CA2 1844/4885CA12 1703/4885 |
| US-11535594-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | CA1 1417/4885CA2 662/4885CA12 3103/4885 |
| US-20080069812-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents | BIRC5, XIAP, BIRC2 | CA1 2515/4885CA2 1895/4885CA12 3333/4885 |
| US-20130071411-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CA1 3380/4885CA2 3146/4885CA12 3326/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | CA1 1669/4885CA2 593/4885CA12 1617/4885 |
| US-20210107875-A1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | PRF1, CASP1, FPR1 | CA1 1417/4885CA2 662/4885CA12 3103/4885 |
| US-20080207525-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates | BIRC5, XIAP, BAX | CA1 2531/4885CA2 1959/4885CA12 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.